Lung cancer (non-small-cell, first line) - gefitinib (TA192)
Fast, easy summary view of NICE guidance on 'lung cancer'
Specific, concise statements that act as markers of high-quality, cost-effective patient care
NICE recommends gefitinib as a possible first treatment for some people with locally advanced or metastatic non-small-cell lung cancer (see below).
Who can have gefitinib?
You should be able to have gefitinib if:
- you have a type of locally advanced or metastatic non-small-cell lung cancer that responds to gefitinib treatment and
- you have not had drug treatment for non-small-cell lung cancer before.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended gefitinib because it is a new type of treatment for locally advanced or metastatic non-small-cell lung cancer which works as well as other treatments available on the NHS and costs about the same.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 08 May 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA192 Gefitinib fel triniaeth gyntaf ar gyfer canser yr ysgyfaint datblygedig neu fetastatig yn lleol lle nad yw'r celloedd yn fach: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.